PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.06 - 0.07
0.06 - 0.24
1.89M / 3.59M (Avg.)
-1.60 | -0.04
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2454289.24%
10Y CAGR of 2454289.24% while CRN.AX is zero. Bruce Berkowitz would see if incremental growth can widen into a significant edge.
3243.04%
5Y CAGR of 3243.04% while CRN.AX is zero. Bruce Berkowitz would see if small improvements can scale into a larger advantage.
66.54%
Positive 3Y CAGR while CRN.AX is negative. John Neff might view this as a sharp short-term edge or successful pivot strategy.
160.42%
OCF/share CAGR of 160.42% while CRN.AX is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
184.59%
OCF/share CAGR of 184.59% while CRN.AX is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
-41.57%
Negative 3Y OCF/share CAGR while CRN.AX stands at 66.22%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
74.81%
10Y net income/share CAGR of 74.81% while CRN.AX is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
-130.87%
Negative 5Y net income/share CAGR while CRN.AX is 0.00%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-165.21%
Negative 3Y CAGR while CRN.AX is 235.38%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-103.80%
Negative equity/share CAGR over 10 years while CRN.AX stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-6.15%
Negative 5Y equity/share growth while CRN.AX is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-258.04%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.